Arnab Chakravarti, MD
College of Medicine
Cancer, Glioblastoma, Glioma, Brain Cancer, Prostatic Cancer, Neoplasm Metastasis, Breast Cancer, Neoplasm Invasiveness, Lung Cancer
I am professor and chair of the Department of Radiation Oncology at The Ohio State University, where I also hold the Max Morehouse Chair of Cancer Research and direct the Brain Tumor Program. In addition, I am a member of the Translational Therapeutics Program at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
Externally, I chair the Board of Directors of the International Society of Neuro-Radiation Biology and am on the Board of Directors of the Ohio Neuro-Oncology Consortium. I also co-chair the Radiation Therapy and Oncology Group (RTOG) Brain Tumor Translational Research Subcommittee and the RTOG Brain Tumor Committee. My leadership roles in these organizations have led to translational research studies that define the standard of care for patients with central nervous system tumors.
My research focus is on translational cancer research, including genomic, epigenomic, transcriptomic and proteomic profiling to detect novel tumor biomarkers that correlate with treatment efficacy and survival. I have received continuous federal funding since 1999 and have served as principal investigator (PI) on National Institutes of Health (NIH) K08, R01, RC2 Go-Grants, and U10, ACA and K12 grants.
My laboratory was among the first to report that deregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas (GBMs) Cancer Research (2002, 2004). We were the first to identify that deregulation of PI3K signaling is significantly associated with adverse clinical outcome in GBM patients (Journal of Clinical Oncology, 2004). This led to some of the first clinical studies to combine radiotherapy with kinase inhibitors for targeting this pathway (International Journal of Radiation Oncology*Biology*Physics, 2012).
I have published more than 120 articles in leading scientific and medical journals, including New England Journal of Medicine, Journal of the American Medical Association, Cancer Cell and Journal of Clinical Oncology. I have delivered numerous distinguished lectureships in the United States, Asia and Europe on the molecular and genetic mechanisms of treatment resistance in cancer, and I have received more than two dozen national and international awards for outstanding clinical care and landmark research accomplishments.